迎接消除慢性乙型肝炎感染的挑战。

StephenW

Genes (Basel). 2019 Apr 1;10(4). pii: E260. doi: 10.3390/genes10040260.
Meeting the Challenge of Eliminating Chronic Hepatitis B Infection.
Revill PA1,2, Penicaud C3, Brechot C4,5,6, Zoulim F7.
Author information

1
    Victorian Infectious Diseases Reference Laboratory, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Melbourne 3000, Australia. [email protected].
2
    Department of Microbiology and Immunology, University of Melbourne at the Peter Doherty Institute for Infection and Immunity, Melbourne 3000, Australia. [email protected].
3
    Directorate, Peter Doherty Institute for Infection and Immunity, Melbourne 3000, Australia. [email protected].
4
    University of South Florida, Tampa, 33612, USA. [email protected].
5
    Romark Laboratory, Tampa, 33607, USA. [email protected].
6
    Global Virus Network, Baltimore; MD 21201-1009, USA. [email protected].
7
    INSERM Unit 1052-Cancer Research Center of Lyon, 69000 Lyon, France. [email protected].

Abstract

Over 257 million people live with chronic hepatitis B virus (HBV) infection and there is no known cure. The effective preventative vaccine has no impact on existing infection. Despite the existence of drugs which efficiently suppress viral replication, treatment is usually life-long and finite therapies that cure HBV infection are urgently required. However, even if such therapies were available today, it is unlikely they would reach all of those who need it most, due to chronic hepatitis B (CHB) being largely undiagnosed across the globe and to the dire need for health systems promoting access to therapy. Considerable challenges to developing and implementing an effective HBV cure remain. Nonetheless, important advances towards a cure are being made, both in the development of a multitude of new therapeutic agents currently undergoing clinical trials, and through the establishment of a new global initiative dedicated to an HBV cure, ICE-HBV, that is working together with existing organisations to fast-track an HBV cure available to all.
KEYWORDS:

HBV cure; ICE-HBV; chronic HBV disease; current clinical trials; persistence; treatment

PMID:
    30939846
DOI:
    10.3390/genes10040260

StephenW

基因（巴塞尔）。 2019年4月1日; 10（4）。 pii：E260。 doi：10.3390 / genes10040260。
迎接消除慢性乙型肝炎感染的挑战。
Revill PA1,2，Penicaud C3，Brechot C4,5,6，Zoulim F7。
作者信息

1
    维多利亚州传染病参考实验室，位于澳大利亚墨尔本3000的Peter Doherty感染和免疫研究所皇家墨尔本医院。 [email protected]。
2
    墨尔本大学微生物学和免疫学系，Peter Doherty感染和免疫研究所，澳大利亚墨尔本3000。 [email protected]。
3
    澳大利亚墨尔本3000感染与免疫研究所Peter Doherty理事会。 [email protected]。
4
    南佛罗里达大学，坦帕，33612，美国。 [email protected]。
五
    Romark Laboratory，Tampa，33607，USA。 [email protected]。
6
    全球病毒网络，巴尔的摩; MD 21201-1009，USA。 [email protected]。
7
    INSERM单位1052-里昂癌症研究中心，69000里昂，法国。 [email protected]。

抽象

超过2.57亿人患有慢性乙型肝炎病毒（HBV）感染，并且没有已知的治愈方法。有效的预防性疫苗对现有感染没有影响。尽管存在有效抑制病毒复制的药物，但治疗通常是终生的，并且迫切需要治疗HBV感染的有限疗法。然而，即使今天有这样的治疗方法，但由于慢性乙型肝炎（CHB）在全球范围内未被严重诊断，并且迫切需要促进获得治疗的卫生系统，因此它们不太可能覆盖所有最需要它的人。 。制定和实施有效的HBV治疗仍存在相当大的挑战。尽管如此，目前正在进行治疗的重要进展，包括目前正在进行临床试验的众多新治疗药物的开发，以及通过建立一项致力于HBV治疗的新全球倡议ICE-HBV，现有组织可以快速跟踪所有人的HBV治疗方法。
关键词：

HBV治愈; ICE-HBV;慢性HBV病;目前的临床试验;持久性;治疗

结论：
    30939846
DOI：
    10.3390 / genes10040260

StephenW

https://www.mdpi.com/2073-4425/10/4/260/pdf

齐欢畅

齐欢畅

Meeting the Challenge of Eliminating Chronic
Hepatitis B Infection